NOTE 7: - SIGNIFICANT EVENTS DURING THE REPORTING PERIOD

On May 27, 2026, the Board of Directors of Revium Rx. (the “Company“) appointed Mr. Igor Bluvstein to serve as Chief Financial Officer of the Company and of its subsidiaries, effective immediately.

In connection with this appointment, Mr. Arie Gordashnikov resigned from his position as Chief Financial Officer of the Company and of its subsidiaries on the same date. Mr. Gordashnikov’s departure did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Resignation of Ms. Inna Martin as Director, Chief Operating Officer and President

On June 10, 2026, Ms. Inna Martin resigned as a director and as Chief Operating Officer and President under a termination agreement with Revium RX Ltd.

The Company recorded an expense of $45 thousand for termination benefits in the quarter, unpaid at June 30, 2026.

Modification of share-based awards. The agreement, approved by the Board on June 16, 2026, extended the exercise period of Ms. Martin’s 2,440,000 vested options to September 30, 2028. As the options were fully vested, the incremental fair value of $111 thousand was recognized immediately in general and administrative expenses against additional paid-in capital, measured using Black-Scholes with a share price of $1.67 and volatility of 85%.